Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon con...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice B., Burge, Russel, Malatestinic, William N., Zhu, Baojin, Zhao, Yunyang, McCormack, Julie, Kimel, Miriam, Merola, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366062/
https://www.ncbi.nlm.nih.gov/pubmed/37434099
http://dx.doi.org/10.1007/s13555-023-00969-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366062/
https://www.ncbi.nlm.nih.gov/pubmed/37434099
http://dx.doi.org/10.1007/s13555-023-00969-1

Ejemplares similares